Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
dasatinib + ropeginterferon alfa-2b
- Development stage
- Phase 2
- Lead developer
- PharmaEssentia
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, Small Molecules
- Administration
- Oral, Subcutaneous
01
Overview
This combination therapy consists of dasatinib, a second-generation BCR-ABL tyrosine kinase inhibitor (TKI), and ropeginterferon alfa-2b, a long-acting monopegylated recombinant interferon alpha-2b. Dasatinib works by inhibiting the BCR-ABL protein and SRC family kinases, which are drivers of leukemic cell proliferation in chronic myeloid leukemia (CML). Ropeginterferon alfa-2b acts as an agonist at the interferon alpha receptor (IFNAR), inducing immunomodulatory effects and direct anti-proliferative activity against malignant clones. The combination is being investigated by M.D. Anderson Cancer Center in Phase II clinical trials for patients with newly diagnosed CML in chronic phase (CML-CP) to evaluate if the addition of interferon can deepen molecular responses and improve the rates of treatment-free remission compared to TKI monotherapy.
- Other names
- dasatinib and ropeginterferon alfa-2bdasatinib plus ropeginterferon alfa-2b
02
Targets
ABL1 (ABL proto-oncogene 1, non-receptor tyrosine kinase)IFNAR (Immune system modulation via type I interferon receptor)SRC (Proto-oncogene tyrosine-protein kinase Src)
Beyond the preview
Go deeper on dasatinib + ropeginterferon alfa-2b.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on dasatinib + ropeginterferon alfa-2b.